PA
MTNB icon

Planning Alternatives’s Matinas BioPharma MTNB Stock Holding History

Planning Alternatives’s Portfolio MTNB Stock Details MTNB Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q3 		– Sell
-200
Closed -$8K – 48
2020
Q2 		$8K Hold
200
– – ﹤0.01% 44
2020
Q1 		$6K Buy
+200
New +$12.1K ﹤0.01% 42

Other funds holding MTNB

BC
Boxer Capital San Diego, California $2.04B AUM 108.39% 1-Year Est. Return
VC
Vivo Capital Palo Alto, California $1.2B AUM 911.44% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return
Victory Capital Management
Victory Capital Management San Antonio, Texas $156B AUM 27.51% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Two Sigma Advisers
Two Sigma Advisers New York $51.4B AUM 31.07% 1-Year Est. Return
BCM
Bridgeway Capital Management Houston, Texas $4.97B AUM 44.96% 1-Year Est. Return
Royal Bank of Canada
Royal Bank of Canada Toronto, Ontario, Canada $570B AUM 27.57% 1-Year Est. Return

Planning Alternatives's MTNB Position: Q3 2020 in Review

Planning Alternatives sold out of Matinas BioPharma (MTNB) in Q3 2020, closing a stake of 200 shares — an estimated $8K sold.

Planning Alternatives first reported a position in MTNB in Q1 2020 and held it in 2 quarters. The position peaked at $8K in Q2 2020. 61 funds tracked by Wall St. Rank hold MTNB as of Q3 2020.

  • Planning Alternatives reported no remaining Matinas BioPharma position as of Q3 2020 after selling out during the quarter.
  • Planning Alternatives sold 200 Matinas BioPharma shares in Q3 2020, an estimated $8K.
  • Planning Alternatives first reported a position in Matinas BioPharma in Q1 2020 and held it in 2 quarters.
  • Planning Alternatives's Matinas BioPharma position peaked at $8K in Q2 2020.
  • 61 funds tracked by Wall St. Rank held Matinas BioPharma as of Q3 2020.

Based on Planning Alternatives's 13F filing for Q3 2020, filed 14 Oct 2020.